Symbol
| LRIG1
| contributors: mct - updated : 08-01-2020
|
HGNC name
| leucine-rich repeats and immunoglobulin-like domains 1
|
HGNC id
| 17360
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
| deletion
|  
|  
|
in various cancers | tumoral
|  
|  
| --low
|  
|
in renal cell carcinoma | tumoral
|  
|  
| --over
|  
|
destabilizes endogenous Met receptor in breast cancer cells and impairs their ability to respond to hepatocyte growth factor | tumoral
|  
|  
| --over
|  
|
suppresses malignant glioma cell growth by attenuating EGFR activity | tumoral
|  
|  
| --low
|  
|
in squamous cell carcinoma of the uterine cervix, with high LRIG2 expression identified women with a very poor prognosis | tumoral
|  
|  
| --over
|  
|
in prostate cancer | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| prognostic biomarker in non-small cell lung cancer | Therapy target
|
System | Type | Disorder | Pubmed |
cancer | brain | | |
feedback negative attenuator of EGFR and could offer a novel therapeutic target to treat patients with malignant gliomas |
| | |
| Lrig1-deficient mice display morphological changes in proximal dendrite arborization and defects in social interaction |